T2 Biosystems Inc. (NASDAQ:TTOO) shares saw unusually-strong trading volume on Monday . Approximately 252,575 shares were traded during trading, an increase of 80% from the previous session’s volume of 140,155 shares.The stock last traded at $5.36 and had previously closed at $5.32.

A number of research analysts have weighed in on TTOO shares. WBB Securities reissued a “buy” rating and set a $11.00 target price on shares of T2 Biosystems in a research report on Friday. BTIG Research lowered shares of T2 Biosystems from a “buy” rating to a “sell” rating and cut their target price for the stock from $12.00 to $4.00 in a research report on Friday. Cantor Fitzgerald reissued a “buy” rating and set a $15.00 target price on shares of T2 Biosystems in a research report on Tuesday, June 21st. Janney Montgomery Scott lowered shares of T2 Biosystems from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 12th. Finally, Leerink Swann reissued an “outperform” rating and set a $11.00 target price on shares of T2 Biosystems in a research report on Monday, June 20th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $10.90.

The company has a 50 day moving average price of $8.38 and a 200 day moving average price of $8.90. The stock’s market capitalization is $126.76 million.

T2 Biosystems (NASDAQ:TTOO) last issued its quarterly earnings results on Monday, May 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.01. The firm earned $1.10 million during the quarter. During the same period last year, the business earned ($0.53) EPS. The company’s quarterly revenue was up 485.1% on a year-over-year basis. Analysts expect that T2 Biosystems Inc. will post ($2.18) earnings per share for the current fiscal year.

In related news, SVP Rahul Dhanda sold 3,589 shares of T2 Biosystems stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $8.16, for a total value of $29,286.24. Following the sale, the senior vice president now owns 3,589 shares of the company’s stock, valued at $29,286.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

A hedge fund recently raised its stake in T2 Biosystems stock. Aisling Capital LLC increased its position in shares of T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems comprises approximately 5.3% of Aisling Capital LLC’s investment portfolio, making the stock its 6th largest position. Aisling Capital LLC owned about 13.89% of T2 Biosystems worth $30,971,000 at the end of the most recent reporting period.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.